Anti-diabetic activity of Swarnamakshika Bhasma and Sandrita Swarnamakshika Bhasma: A comparative in-vivo study
AYU (An International Quarterly Journal of Research in Ayurveda) · 2025-01 · 46 (1) · 56-64
DOI: 10.4103/ayu.ayu_326_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift AYU (An International Quarterly Journal of Research in Ayurveda), online erschienen am 10.12.2025. Verfasst von AT Dalvi und 5 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Swarnamakshika Bhasma (SMB) is one of the well-known drug, and its formulations are mainly indicated in Meha (polyuria disorders). Ayurvedic pharmacopoeia of India has mentioned another variety of Swarnamakshika (SM), i.e., Sandrita SM (concentrated ore of SM having 12% of copper; SSM), having the same indications as SMB. Diabetes is a chronic, metabolic disease that affects the millions of people worldwide and 422 million people worldwide live with diabetes. Diabetes directly causes around 1.5 million deaths annually. Despite having similar therapeutic indications, limited data are available regarding the comparative efficacy of the SMB and Sandrita SMB (SSMB). Hence, there is a need to generate the scientific data on comparative in vivo anti-diabetic efficacy of SMB and SSMB.
Aim
The present study attempt has been made to assess and compare the anti-diabetic activity of SMB and SSMB. Materials and methods: For anti-diabetic activity, streptozotocin administered rats with blood sugar levels (BSL) >200 mg/dL were divided into six groups. Group I served as a nondiabetic control group, group II served as diabetic control (DC) group, group III was the standard control and administered with glibenclamide (0.65 mg/kg), group IV was vehicle control group and was administered with honey (10 ml/kg), group V was administered with SMB (22.50 mg/kg), and group VI was administered with SSMB (22.50 mg/kg) for 21 days. Results of the study were assessed on the basis of BSL, liver function tests, kidney function tests, and histopathological changes.
Results
Both the SMB and SSMB exhibited a significant decrease in BSL ( P < 0.05) compared to the respective initial value (paired t -test, P < 0.05) and the DC group (unpaired t -test, P < 0.05). Histopathologically, nonsignificant changes were observed in any organ except mild to moderate fatty changes in the kidney in both the test drug-treated groups.
Conclusion
SMB and SSMB have significant anti-diabetic activities in experimental models. SSMB has a comparatively better anti-diabetic effect than that of SMB.
Zitieren
APA
Dalvi, A., Ghetiya, H., Dilip, P., Nariya, M., Bedarkar, P., & Patgiri, B. (2025). Anti-diabetic activity of Swarnamakshika Bhasma and Sandrita Swarnamakshika Bhasma: A comparative in-vivo study. AYU (An International Quarterly Journal of Research in Ayurveda), 46(1), 56-64. https://doi.org/10.4103/ayu.ayu_326_24
Vancouver
Dalvi A, Ghetiya H, Dilip P, Nariya M, Bedarkar P, Patgiri B. Anti-diabetic activity of Swarnamakshika Bhasma and Sandrita Swarnamakshika Bhasma: A comparative in-vivo study. AYU (An International Quarterly Journal of Research in Ayurveda). 2025;46(1):56-64. doi:10.4103/ayu.ayu_326_24
BibTeX
@article{Dalvi2025,
author = {Dalvi, AT and Ghetiya, H and Dilip, P and Nariya, MB and Bedarkar, P and Patgiri, BJ},
title = {Anti-diabetic activity of Swarnamakshika Bhasma and Sandrita Swarnamakshika Bhasma: A comparative in-vivo study},
journal = {AYU (An International Quarterly Journal of Research in Ayurveda)},
year = {2025},
volume = {46},
number = {1},
pages = {56--64},
doi = {10.4103/ayu.ayu_326_24}
}
EUVIMED